Valuation: Alaunos Therapeutics, Inc.

Market Cap 50.48L 44.27L 41.01L 37.73L 71.36L 48Cr 72.75L 4.89Cr 1.92Cr 24Cr 1.9Cr 1.85Cr 82Cr P/E 2024
-0.65x
P/E 2025 -1.47x
Enterprise Value 36.63L 32.13L 29.75L 27.38L 51.78L 35Cr 52.79L 3.55Cr 1.39Cr 17Cr 1.38Cr 1.35Cr 59Cr EV / Sales 2024
19,59,38,500x
EV / Sales 2025 1,16,47,61,400x
Free-Float
85.49%
Yield 2024 *
-
Yield 2025 -
1 day-1.15%
1 week+0.49%
Current month-9.29%
1 month-10.09%
3 months-31.44%
6 months-25.18%
Current year-36.53%
1 week 1.98
Extreme 1.98
2.22
1 month 1.98
Extreme 1.98
2.48
Current year 1.92
Extreme 1.92
4.04
1 year 1.67
Extreme 1.67
4.59
3 years 1.31
Extreme 1.3137
75
5 years 1.31
Extreme 1.3137
601.5
10 years 1.31
Extreme 1.3137
1,182
Manager TitleAgeSince
Chief Executive Officer 63 02/07/2025
Director of Finance/CFO 41 22/02/2025
Director TitleAgeSince
Director/Board Member 57 16/12/2020
Chairman 63 22/09/2023
Director/Board Member 72 05/02/2021
Date Insider Type Main position Quantity % Market Cap.
30/06Free

Chief Executive Officer

3,880 0.1589%
12/06Free

Chief Executive Officer

7,761 0.3178%
22/05Free

Chief Executive Officer

3,700 0.1556%
Change 5-day change 1-year change 3-year change Capi.($)
-1.15%+0.49%-48.75%-97.09% 50.48L
-2.48%-2.22%+55.85%+79.12% 5.35TCr
-0.13%-6.75%+55.40%+126.77% 5.42TCr
+0.14%-3.48%+6.89%+428.69% 2.37TCr
-1.10%-5.92%-20.08%-18.04% 2.28TCr
+2.36%+3.86%+42.80%-6.60% 1.95TCr
-2.21%-2.19%+35.20%-29.33% 1.78TCr
-2.72%-4.04%+187.08%+362.09% 1.6TCr
-1.15%-3.07%+45.33%+654.85% 1.54TCr
-0.93%-2.53%+22.06%+186.93% 1.41TCr
Average -0.97%-1.82%+38.18%+168.74% 2.37TCr
Weighted average by Cap. -1.02%-1.99%+47.11%+163.21%

Financials

2024 2025
Net sales 0.01 0.01 0.01 0.01 0.01 0.96 0.01 0.1 0.04 0.47 0.04 0.04 1.62 0 0 0 0 0.01 0.48 0.01 0.05 0.02 0.24 0.02 0.02 0.81
Net income -46.79L -41.04L -38.01L -34.97L -66.15L -45Cr -67.44L -4.53Cr -1.78Cr -22Cr -1.76Cr -1.72Cr -76Cr -41.76L -36.63L -33.92L -31.21L -59.04L -40Cr -60.19L -4.04Cr -1.59Cr -20Cr -1.57Cr -1.53Cr -68Cr
Net Debt -10.91L -10L -9L -8L -15.42L -10Cr -15.72L -1.06Cr -41.43L -5.13Cr -40.97L -40.07L -18Cr -13.85L -12.15L -11.25L -10.35L -19.58L -13Cr -19.96L -1.34Cr -52.59L -6.51Cr -52.01L -50.87L -22Cr
Logo Alaunos Therapeutics, Inc.
Alaunos Therapeutics, Inc. is a pre-clinical obesity and metabolic disorder and clinical-stage oncology-focused cell therapy company. The Company focuses on developing small molecules that are expected to be efficacious against obesity and other metabolic disorders. The Company is engaged in developing novel small molecule-based obesity therapeutics. The Company’s operations consist primarily of conducting research and development and raising capital to fund those efforts. The Company has not generated any revenues.
Employees
1
Date Price Change Volume
14/26/14 $2.050 -1.63% 499
13/26/13 $2.084 +1.66% 7,548
10/26/10 $2.050 -0.97% 10,715
09/26/09 $2.070 0.00% 19,136
08/26/08 $2.070 +1.47% 61,259

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TCRT Stock